ATIP - ATI Physical Therapy, Inc.
NYSE
->
Healthcare
->
Medical Care Facilities
Bolingbrook,
United States
Type: Equity
ATIP price evolution
ATIP
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $23.46 | $32.96 | $23.73 | $36.8 |
| Short term investments | ||||
| Net receivables | $124.09 | $129.09 | $129.2 | $112.49 |
| Inventory | ||||
| Total current assets | $160.32 | $176.88 | $166.17 | $168.64 |
| Long term investments | ||||
| Property, plant & equipment | $266.57 | $273.33 | $285.31 | $294.85 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $967.28 | $990.54 | $991.49 | $1003.28 |
| Current liabilities | ||||
| Accounts payable | $16.73 | $10.93 | $10.86 | $14.7 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $143.66 | $151.21 | $139.72 | $156.45 |
| Long term debt | $550.27 | $531.17 | $534.89 | $513.05 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $894.42 | $886.04 | $885.1 | $883.89 |
| Shareholders' equity | ||||
| Retained earnings | -$1461.51 | -$1427.69 | -$1423.96 | -$1409.31 |
| Other shareholder equity | $0.06 | $0.15 | $0.27 | $0.41 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $36.8 | $83.14 | $48.62 | $1.31 |
| Short term investments | ||||
| Net receivables | $112.49 | $80.67 | $82.45 | $90.71 |
| Inventory | ||||
| Total current assets | $168.64 | $194.13 | $143.58 | $1.66 |
| Long term investments | ||||
| Property, plant & equipment | $294.85 | $349.78 | $396.38 | $395.4 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $345.02 | |||
| Total investments | ||||
| Total assets | $1003.28 | $1078.98 | $1562.69 | $346.68 |
| Current liabilities | ||||
| Accounts payable | $14.7 | $12.56 | $15.15 | $1.57 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $156.45 | $116.52 | $137.33 | $1.69 |
| Long term debt | $513.05 | $531.6 | $543.8 | $1154.75 |
| Total noncurrent liabilities | $339.99 | |||
| Total debt | ||||
| Total liabilities | $883.89 | $894.69 | $1058.28 | $341.68 |
| Shareholders' equity | ||||
| Retained earnings | -$1409.31 | -$1339.51 | -$847.13 | -$13.61 |
| Other shareholder equity | $0.41 | $4.9 | $0.03 | -$0 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $189.99 | $188.11 | $181.47 | $182.29 |
| Cost of revenue | ||||
| Gross Profit | $29.93 | $32.4 | $26.88 | $30.46 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $28.69 | $25.52 | $31.18 | $27.89 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.13 | -$0.01 | -$0.13 | $2.29 |
| Interest expense | -$33.51 | -$9.28 | -$9.08 | $1.03 |
| Net income | ||||
| Net income | -$40.85 | -$10.56 | -$19.27 | -$8.94 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $699.02 | $635.7 | ||
| Cost of revenue | ||||
| Gross Profit | $108.05 | $75.1 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $129.98 | $128.5 | $1.61 | |
| Operating income | -$1.61 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $2.57 | -$48.5 | ||
| Interest expense | -$36.57 | -$45.3 | ||
| Net income | ||||
| Net income | -$131.97 | -$492.4 | -$13.61 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$8.73 | -$5.15 | -$2.49 | -$17.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $26.79 | $29.16 | $28.48 | -$16.61 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$13.34 | -$3.84 | -$13.07 | -$46.34 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$13.61 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.56 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$17.37 | -$28.05 | -$39.89 | -$345 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$16.61 | $128.08 | -$11.52 | $346.87 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$46.34 | $34.52 | -$93.51 | $1.31 |
News
Fundamentals
| Market cap | $2.86M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 4.24M |
| Revenue | $741.86M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$79.62M |
| Revenue Q/Q | 21.17% |
| Revenue Y/Y | N/A |
| P/E ratio | -0.04 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.00 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 5.54 |
| EPS | -$18.80 |
|---|---|
| ROA | -8.06% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.12 |
| Quick ratio | N/A |